4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $124,770.75 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 12,415 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $10.05, for a total value of $124,770.75. Following the completion of the transaction, the insider directly owned 871,737 shares of the company’s stock, valued at $8,760,956.85. This represents a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Kirn also recently made the following trade(s):

• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.03, for a total transaction of $189,171.75.
• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.87, for a total transaction of $548,364.96.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.47, for a total transaction of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $19,258.44.

4D Molecular Therapeutics Trading Up 2.6%

Shares of FDMT stock opened at $10.55 on Friday. 4D Molecular Therapeutics, Inc. has a 1 year low of $5.33 and a 1 year high of $14.00. The firm’s 50 day moving average is $10.70 and its 200-day moving average is $9.73. The firm has a market capitalization of $551.55 million, a price-to-earnings ratio of -4.11 and a beta of 2.73.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The company had revenue of $3.05 million during the quarter, compared to analyst estimates of $2.59 million. On average, equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a research note on Friday, May 8th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. B. Riley Financial started coverage on 4D Molecular Therapeutics in a research report on Friday, July 31st. They issued a “buy” rating and a $37.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $30.67.

Institutional Trading of 4D Molecular Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in FDMT. Janus Henderson Group PLC increased its holdings in 4D Molecular Therapeutics by 164.4% in the fourth quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after purchasing an additional 2,882,508 shares during the last quarter. State Street Corp lifted its stake in 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after buying an additional 1,785,106 shares during the period. RA Capital Management L.P. boosted its holdings in 4D Molecular Therapeutics by 23.9% during the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock worth $42,399,000 after buying an additional 1,090,000 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in 4D Molecular Therapeutics by 605.8% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock worth $9,264,000 after buying an additional 1,060,156 shares during the last quarter. Finally, Evergreen Quality Fund GP Ltd. acquired a new position in shares of 4D Molecular Therapeutics during the 4th quarter worth about $7,136,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.